This post was originally published on this site The Alzheimer’s Association estimates that nearly 5.8 million people in the United States have the condition. Most people who are diagnosed with Alzheimer’s disease are 65 or older, but the disease is found across all age groups, including 200,000 with an early-onset diagnosis. The adage that “there’s…
About Alzheimer’s Disease
Walking into a room and forgetting why you went into the room is normal. Walking into a room and forgetting what room you are in is not normal. Alzheimer’s disease is the most common form of dementia and affects one in ten people over the age of 65. Unfortunately, the exact cause of Alzheimer’s disease is not fully understood however leading scientific experts in the field attribute the illness to the irreversible and progressive generalized degeneration of the brain. Alzheimer’s disease goes well beyond the forgetfulness that may accompany aging, and typically first signs include difficulty remembering current information or performing new tasks. Ongoing hallmark symptoms include impaired memory function, difficulty performing everyday tasks, and neurobehavioral abnormalities. Currently, there is no known cure for Alzheimer’s disease, and multi-disciplinary treatment focuses on symptom management and limiting progression.
Conditions
Alzheimer’s News
New Research Unit at England’s University of East Anglia to Study Possible Link Between Sleep and Dementia
This post was originally published on this site To enable researchers to study prospective links between sleep and dementia, a cutting-edge sleep unit has opened at the University of East Anglia (UEA) in Norwich, England. While sleeping issues commonly occur in dementia, it’s unclear whether diseases such as Alzheimer’s cause the disturbances, or whether problems sleeping…
Phase 1 Trial of Alzheimer’s Candidate SM07883 Doses First Participant
This post was originally published on this site A Phase 1 trial evaluating Samumed’s investigational compound SM07883 for Alzheimer’s disease has dosed its first participant. The Phase 1 trial (ACTRN12619000327189), taking place in Australia, will assess the safety, tolerability, and pharmacokinetics (the movement of a medicine into, through, and out of the body) of ascending…
My Recommended Resources for Alzheimer’s Caregivers
This post was originally published on this site Caring for someone with Alzheimer’s disease is much more challenging than most people realize. The stress of taking over a dementia patient’s financial and personal responsibilities, as well as managing their care is exhausting. During the later stages of the disease, patients with dementia need continual help…
Investigational Azeliragon May Lessen Cognitive Decline in Mild Alzheimer’s Disease Patients with Type 2 Diabetes, Analysis Finds
This post was originally published on this site The investigational therapy azeliragon decreased inflammation and lessened cognitive decline and dementia in patients with mild Alzheimer’s disease and type 2 diabetes, compared with a placebo, according to data from a subgroup analysis of the Phase 3 STEADFAST study. The findings were described in the presentation, “Inflammatory Biomarkers,…
Treading Dark Waters
This post was originally published on this site Alzheimer’s disease is cruel. And its cruelty is unparalleled, robbing patients and stripping entire families of what they hold dearest. Definite characteristics are associated with this mind-altering condition, one of which is an unfortunate outcome. But if you’re in the throes of the disease, you already know…
Gantenerumab Continues to Show Promise in Reduction of Amyloid Plaques
This post was originally published on this site Latest findings from the open-label extension (OLE) Phase 3 clinical trials Scarlet RoAD (NCT01224106) and Marguerite RoAD (NCT02051608) on gantenerumab (RG1450, RO4909832) continue to show significant reductions in the accumulation of amyloid plaques in patients with Alzheimer’s disease with and without amyloid-related imaging abnormalities-edema (ARIA-E). The findings…
UB-311 Vaccine Safe in Mild Alzheimer’s Patients, Phase 2a Trial Shows
This post was originally published on this site United Neuroscience’s vaccine candidate UB-311 was safe and well-tolerated in patients with mild Alzheimer’s disease, according to results from a Phase 2a clinical trial. Patients who participated in this trial are now eligible to enroll in a long-term follow-up study that will continue to assess the vaccine’s safety…
Antiviral Medicine Could Help Halt Cognitive Decline in Early Alzheimer’s, Preliminary Data Show
This post was originally published on this site Preliminary data from a Phase 2 study suggests that treating early Alzheimer’s disease patients who are positive for herpes simplex virus with an antiviral medicine may help halt their cognitive decline. Hugo Lövheim, MD, PhD, at Umeå University, Sweden, presented the results in a presentation titled “Valz…
AVP-786 Relieves Agitation in Alzheimer’s Patients, Preliminary Trial Results Show
This post was originally published on this site AVP-786, an investigational oral therapy, significantly relieved agitated behaviors among patients with Alzheimer’s dementia, according to preliminary data from a worldwide Phase 3 trial by Avanir Pharmaceuticals. The treatment candidate was designed as a second-generation version of Nuedexta, a two-drug combo approved for pseudobulbar affect. AVP-786 is…
ALZ-101 Vaccine Fares Well in Preclinical Study of Alzheimer’s Fish
This post was originally published on this site Alzinova‘s ALZ-101 vaccine — designed to target toxic forms of the amyloid beta protein that drive neurodegeneration in Alzheimer’s disease — was well-tolerated in non-human primates and displayed efficacy in a fish model of the disease. A clinical study in patients with early Alzheimer’s disease now is expected to…
Music and Laughter Are Strong Medicine Against Dementia
This post was originally published on this site When my 67-year-old mother was diagnosed with stage 4 uterine cancer I was devastated. My mother already was disabled from depression and fibromyalgia, so being diagnosed a few months later with Alzheimer’s disease along with terminal cancer seemed like a cruel joke. Soon after I learned of…